TY  - JOUR
AU  - Calvo, Aitana
AU  - Alonso, Saioa
AU  - Prieto, Esther
AU  - Ascaso del Río, Ana
AU  - Ortuño, Jordi
AU  - Fernández, Nieves
AU  - Portolés Pérez, Antonio
PY  - 2022
DO  - 10.3390/jcm11030858
SN  - 2077-0383
UR  - https://hdl.handle.net/20.500.14352/71632
T2  - Journal of Clinical Medicine
AB  - Carisoprodol was authorised in 1959 without a full pharmacokinetic–pharmacodynamic (PK–PD) characterisation. We designed a crossover, double-blind, placebo-controlled, randomized clinical trial to characterize the PKs of carisoprodol and its main...
LA  - eng
M2  - 858
PB  - MPDI
KW  - carisoprodol
KW  - meprobamate
KW  - pharmacokinetics
KW  - phenotype
KW  - 2C19
KW  - clinical trial
KW  - drug abuse liability
KW  - central muscle relaxants
TI  - Single and Multiple Dose PK–PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers
TY  - journal article
VL  - 11
ER  -